Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors

Endocrinology

Volumn 137, Issue 9, 1996, Pages 3936-3941

  Gardella, Thomas J ^a   Luck, Michael D ^a   Jensen, Geoffrey S ^a   Schipani, Ernestina ^a   Potts Jr, John T ^a   Jüppner, Harald ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; MUTANT PROTEIN; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; SECRETIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CHONDRODYSPLASIA; CONTROLLED STUDY; GENE MUTATION; METAPHYSIS; MOLECULAR CLONING; MONKEY; NONHUMAN; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR UPREGULATION;

EID: 0029816971     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.137.9.8756569     Document Type: Article

References (40)

1. Braestrup C, Schmiechen R, Neef G, Nielsen M, Petersen EN 1982 Interaction of convulsive ligands with benzodiazepine receptors. Science 216:1241-1243
2. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, Lefkowitz RJ 1992 Constitutive activation of the α1B-adrenergic receptor by all amino acid substitutions at a single site. J Biol Chem 1942:1430-1433
3. Samama P, Pei G, Costa T, Cotecchia S, Lefkowitz RJ 1994 Negative antagonists promote an inactive conformation of the β2-adrenergic receptor. Mol Pharmacol 45:390-394
4. Costa T, Herz A 1989 Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325
5. Costa T, Ogino Y, Munson PJ, Onaran O, Rodbard D 1992 Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41:549-560
6. Barker E, Westphal R, Schmidt D, Sanders-Bush E 1994 Constitutively active 5-hydroxytryptamine2c receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269:11687-11690
7. Matus LN, Nussenzveig DR, Gershengorn MC, Oron Y 1995 Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenopus oocytes and AtT20 cells. J Biol Chem 270:1041-1047
8. Heinflink M, Nussenzveig D, Grimberg H, Lupo-Meiri M, Oron Y, Gershengorn M 1995 A constitutively active mutant thyrotropin-releasing hormone recptor is chronically down-regulated in pituitary cells: evidence using chlordiazepoxide as a negative antagonist. Mol Endocrinol 9:1455-1460
9. Bond R, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF, Lefkowitz RJ 1995 Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor. Nature 374:271-276
10. Milligan G, Bond R, Lee M 1995 Inverse agonism: pharmacological curiosity or potential therapeutic strategy. Trends Pharmacol Sci 16:10-13
11. Abou-Samra AB, Jüppner H, Force T, Freeman M, Kong XF, Schipani E, Urena P, Richards J, Bonventre JV, Potts JT Jr, Kronenberg HM, Segre GV 1992 Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 89:2732-2736
12. Jüppner H, Abou-Samra A-B, Freeman M, Kong X-F, Schipani E, Richards J, Kolakowski LF Jr, Hock J, Potts JT Jr, Kronenberg HM, Segre GV 1991 A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024-1026
13. Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, Kolakowski LF Jr, Lodish HF, Goldring SR 1991 Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254:1022-1024
14. Ishihara T, Nakamura S, Kaziro Y, Takahashi K, Takahashi K, Nagata S 1991 Molecular cloning and expression of a cDNA encoding the secretin receptor. EMBO J 10:1635-1641
15. Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch PA, Kuijper JL, Sheppard PO, Sprecher CA, O'Hara PJ, Foster D, Walker KM, LHJ C, McKernan PA, Kindsvogel W 1993 Expression cloning and signaling properties of the rat glucagon receptor. Science 259:1614-1616
16. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VLJ, Kronenberg HM, Mulligan RC 1994 Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8:277-289
17. Kronenberg HM, Bringhurst FR, Nussbaum SR, Jüppner H, Abou-Samra AB, Segre GV, Potts Jr JT 1993 Parathyroid hormone: Biosynthesis, secretion, chemistry and action. In: Mundy GR Martin TJ (eds) Handbook of Experimental Pharmacology. Springer-Verlag, Heidelberg, pp 185-201
18. Goltzman D, Peytremann A, Callahan E, Tregear GW, Potts Jr JT 1975 Analysis of the requirements for parathyroid hormone action in renal membranes with the use of inhibiting analogues. J Biol Chem 250:3199-3203
19. Horiuchi N, Holick MF, Potts JT Jr, Rosenblatt M 1983 A parathyroid hormone inhibitor in vivo: design and biologic evaluation of a hormone analog. Science 220:1053-1055
20. Chorev M, Goldman ME, McKee RL, Roubini E, Levy J, Gay T, Reagan JE, Fisher JE, Caporale LH, Golub EE, Caulfield MP, Nutt RF, Rosenblatt M 1990 Modifications of position 12 in parathyroid hormone and parathyroid hormone related protein: toward the design of highly potent antagonists. Biochemistry 29:1580-1586
21. Goldman ME, McKee RL, Caulfield MP, Reagan JE, Levy JJ, Gay CT, DeHaven PA, Rosenblatt M, Chorev M 1988 A new highly potent parathyroid hormone antagonist: [D-Trp12,Tyr34]bPTH-(7-34)NH2. Endocrinology 123:2597-2599
22. 2 by substitution of PTH amino acids at positions 10 and 11. Endocrinology 127:491-493
23. McKee RL, Caulfield MP, Rosenblatt M 1990 Treatment of bone-derived ROS 17/2.8 cells with dexamethasone and pertussis toxin enables detection of partial agonist activity for parathyroid hormone antagonists. Endocrinology 127:76-82
24. Gardella TJ, Axelrod D, Rubin D, Keutmann HT, Potts Jr JT, Kronenberg HM, Nussbaum SR 1991 Mutational analysis of the receptor-activating region of human parathyroid hormone. J Biol Chem 266:13141-13146
25. Schipani E, Kruse K, Jüppner H 1995 A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98-100
26. Schipani E, Langman CB, Parfitt AM, Jensen GS, Kikuchi S, Kooh SW, Cole WG, Jüppner H, Constitutively activated receptors for parathyroid hormone/ parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. New Engl J Med, in press
27. Schipani E, Karga H, Karaplis AC, Potts Jr JT, Kronenberg HM, Segre GV, Abou-Samra AB, Jüppner H 1993 Identical complementary deoxyribonucleic acids encode a human renal and hone parathyroid hormone (PTH)/PTH-related peptide receptor. Endocrinology 132:2157-2165
28. Seed B, Aruffo A 1987 Molecular Cloning of the CD2 Antigen, the T-cell Erythrocyte Receptor. Proc Natl Acad Sci USA 84:3365-3369
29. Lee C, Luck M, Juppner H, Potts J, Kronenberg H, Gardella T 1995 Homolog-scanning mutagenesis of the parathyroid hormone receptor reveals PTH-(1-34)-binding determinants in the third extracellular loop. Mol Endocrinol 9:1269-1278
30. Bowen W, Jerman J 1995 Nonlinear regression using spreadsheets. Trends Pharmacol Sci 16:413-417
31. Huang Z, Chen Y, Nissenson RA 1995 The cytoplasmic tail of the G-protein-coupled receptor for parathyroid hormone and parathyroid hormone-related protein contains positive and negative signals for endocytosis. J Biol Chem 270:151-156
32. Ren Q, Kurose H, Lefkowitz RJ, Cotecchia S 1993 Constitutively active mutants of the α2-adrenergic receptor. J Biol Chem 268:16483-16487
33. Pei G, Samama P, Lohse M, Wang M, Codina J, Lefkowitz R 1994 A constitutively active mutant b2-adrenergic receptor is Constitutively desensitized and phosphorylated. Proc Natl Acad Sci USA 91:2699-2702
34. De Lean A, Stadel J, Lefkowitz R 1980 A Ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255:7108-7117
35. Samama P, Cotecchia S, Costa T, Lefkowitz R 1993 A mutation-induced activated state of the β2-adrenergic receptor: extending the ternary complex model. J Biol Chem 268:4625-4636
36. Spalding T, Burstein E, Brauner-Osborne H, Hill-Eubanks D, Brann M 1995 Pharmacology of a Constitutively active muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther
37. 2+ cascades. Mol Endocrinol 9:725-733
38. Kosugi S, Van DC, Geffner ME, Rabl W, Carel JC, Chaussain JL, Mori T, Merendino JJ, Shenker A 1995 Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum Mol Genet 4:183-188
39. Latronico AC, Anasti J, Arnhold IJ, Mendonca BB, Domenice S, Albano MC, Zachman K, Wajchenberg BL, Tsigos C 1995 A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty. J Clin Endocrinol Metab 80:2490-2494
40. 2+-sensing receptor gene mutation. Nature Genet 8:303-307